USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ENANTIGEN THERAPEUTICS, INC.
Address:
3805 OLD EASTON RD
DOYLESTOWN, PA 18902-8400
Phone:
(215) 589-6350
URL:
EIN:
126156958
DUNS:
828761697
Number of Employees:
10
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,177,154.00 4
STTR Phase I $99,967.00 1
STTR Phase II $738,292.00 1

Award List:

Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$99,967.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
Neville R. Kallenbach, Professor of Chemistry
Research Institution:
New York University
RI Contact:
Eric Bybee
Abstract:
This project addresses two pressing problems in treating bacterial infections: the emerging resistance against current antibiotics and the role of biofilm formation in these infections. Based ona successful lead dendrimerthat acts against a broad spectrum of MDR pathogens including A.baumannii, and… More

Development of a Therapy for Dengue Virus Infection

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$282,480.00
Agency:
HHS
Principal Investigator:
Xiaodong Xu
Abstract:
DESCRIPTION (provided by applicant): This is a Phase I proposal to develop a new family of imino sugars, with break through , unprecedented, potency, for the treatment of dengue virus (DENV) infection. There is currently no effective treatment for disease s caused by this virus and both the public… More

Novel Antimicrobial Agents Targeting Drug Resistant Bacterial Biofilms

Award Year / Program / Phase:
2012 / STTR / Phase II
Award Amount:
$738,292.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Xiaodong X. PhD, President – (215) 589-6350
Research Institution:
New York University
RI Contact:
Richard Louth
Abstract:
This project builds on patterns derived from natural antimicrobial peptide sequences to develop novel compounds with better systemic activity, lower cytotoxicity and broader spectrum activity against multidrug resistant (MDR) pathogens. In Phase I and the

Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Xiaodong Xu – 215-589-6350
Abstract:
DESCRIPTION (provided by applicant): This is a proposal to develop newly discovered sulfamoylbenzamide derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, a… More

Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$294,674.00
Agency:
HHS
Principal Investigator:
Xiaodong Xu – 215-589-6350
Abstract:
DESCRIPTION (provided by applicant): This is a phase I proposal to determine the feasibility of developing newly discovered fluorinated sulfamoylbenzamide (FSBA) derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as… More

Neural Probe for high spatial and temporal resolution detection of cocaine and su

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Andrea Cuconati – 215-489-4918
Abstract:
DESCRIPTION (provided by applicant): This is a proposal to implement a novel high throughput assay system to detect inhibitors of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) formation and/or maintenance. HBV cccDNA is essential to the virus life cycle and its elimination during… More